Sernova Biotherapeutics reports developments tied to its clinical-stage regenerative medicine programs, including the Cell Pouch Bio-hybrid Organ being developed for type 1 diabetes. Company news centers on clinical and regulatory updates, research collaborations involving donor cells, stem-cell derived islet-like clusters and immunosuppression approaches, and the advancement of its bio-hybrid organ platform.
Recurring updates also cover Sernova's capital structure, including private placements, debt settlements, convertible debentures, warrant issuances and debt-to-equity conversions. Governance items include annual meeting results, board composition and shareholder voting matters.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Sernova Corp. (TSX:SVA; OTCQB:SEOVF) announced promising preclinical results for its partnership with Evotec SE, focusing on iPSC-derived islet-like clusters (ILCs) for treating Type 1 Diabetes (T1D). Key findings showcased that Evotec's scalable GMP manufacturing process yields ILCs with high insulin-producing beta cell content and successful glycemic control in diabetic mouse models. Results indicated that ILCs implanted in Sernova's Cell Pouch demonstrated blood sugar normalization akin to human islets over a 320-day study. The companies are on track for an IND filing and Phase 1/2 clinical trial in 2024, aiming to offer a commercially viable off-the-shelf treatment for diabetes. The preclinical data was presented at the IPITA/HSCI/JDRF Summit in April 2023, underscoring the significant potential for a 'functional cure' for T1D.
Sernova Corp. (OTCQB:SEOVF), a leader in cell therapeutics, announces that CEO Dr. Philip Toleikis will present at the Cell & Gene Meeting on the Med in Barcelona, Spain, from April 12-14, 2023. The presentation, titled Navigating CGTx Development in 2023, is scheduled for April 12, 2023, from 4:45 PM to 5:30 PM CET at the BioCentriq Ballroom. Virtual attendance will be available, providing access to Sernova’s presentation and all on-demand conference sessions. Credentialed investors can attend for free by contacting Laura Stringham. Sernova focuses on developing cell therapies for chronic diseases, including its Cell Pouch System aimed at providing a functional cure for insulin-dependent diabetes. This system fosters the long-term survival of therapeutic cells, promising advancements in treating chronic conditions.
Sernova Corp. addressed misleading claims from dissident shareholders regarding its board renewal process and proxy battle. The company asserts that its management has positioned Sernova for value creation, evidenced by a 17% year-to-date share price increase, outperforming the 8% decline in the Nasdaq XBI biotech index. Despite challenges in the biotech sector, Sernova's clinical trial advancements and technology partnerships, specifically with Evotec SE, are poised to enhance shareholder value. Upcoming milestones include clinical trial updates for type-1 diabetes and a hypothyroid disease program. Sernova ended Q1 2023 with cash resources of $45.6 million, providing a solid financial foundation for ongoing and future projects.
Sernova Corp. (OTCQB:SEOVF) announced that an abstract will be presented at the American Diabetes Association 83rd Scientific Sessions from June 23-26, 2023, in San Diego, CA. The abstract titled "Islet Allotransplantation into Pre-vascularized Sernova Cell Pouch" will be delivered on June 24 at 5:15 PM PT. This significant presentation showcases early results from the University of Chicago concerning Sernova's innovative Cell Pouch System, which aims to provide a functional cure for insulin-dependent diabetes. The study may impact future treatment approaches and is part of Sernova's broader strategy to develop cell therapies for chronic diseases.
Sernova Corp. (OTCQB:SEOVF) announced its first pre-clinical data presentation regarding the Cell Pouch with Evotec’s iPSC-derived islet-like clusters for type 1 diabetes (T1D). The presentation is set for April 24, 2023, at the 4th International Pancreas and Islet Transplant Association Summit in Cambridge, Massachusetts. This collaboration aims to develop a scalable process for manufacturing insulin-producing cells from induced pluripotent stem cells (iPSCs) for cell therapy. Sernova’s ongoing Phase 1/2 study demonstrates the potential of the Cell Pouch System as a functional cure for T1D.
Sernova Corp. (OTCQB:SEOVF) announced the implantation of the third patient with its advanced 10-chamber Cell Pouch in a Phase 1/2 trial for type 1 diabetes treatment. The company expects to report interim data from the second patient cohort in Q4 2023.
The new cohort includes up to seven patients, and the protocol is designed to optimize islet transplant efficacy. The 10-channel Cell Pouch offers over 50% more capacity than previous models, aiming to reduce severe hypoglycemic episodes and insulin dependency. The interim results from this trial phase are highly anticipated, as they may indicate pivotal advancements in diabetes treatment.